Clinical Trial Update: A Multi-Center Study of Ibrutinib in Combination With MEDI4736 in Subjects With Relapsed or Refractory Solid Tumors [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial evaluating ibritinib in combination with MEDI4736 in relapsed/refractory solid tumors completed with results posted in 2019.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Non-small Cell Lung Cancer
• Pancreatic Cancer

Drugs mentioned

• Ibrutinib (ibrutinib)
• MEDI4736 (Durvalumab)

Snippet

Sponsor: Pharmacyclics LLC. | Conditions: Non-Small Cell Lung Cancer, Breast Cancer | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2019-01-03